CRL Kewajiban utang agregat Charles River

The overall state of liabilities in GURU.Markets helps assess the impact of partnerships with biotech startups on capital. 2.92 is the current level of this metric, reflecting the ambition of Charles River Laboratories (CRL) to monopolize the early-stage development segment. Debt stability confirms the business's resilience to economic cycles, as demand for medical innovations remains constant regardless of market conditions.

Gunggung utang perusahaan: Charles River Lab (CRL) kanggo 04.07.2022 - 28.10.2026

Rincian analitis perusahaan Charles River Laboratories

- rega lan prakiraan konsensus rega:

Rega saham Charles River Corp|CRL - Bagan rega target

- data kapitalisasi pasar:

Nilai pasar Charles River Lab|CRL - Nilai Total Perusahaan

- data kapitalisasi buku:

Nilai Akuntansi saben Saham Charles River|CRL - Kapitalisasi Buku|Rasio Kapitalisasi Pasar marang Nilai Buku criver.com|CRL - Gunggung Aset Perusahaan

- data utang lan likuiditas:

Rasio Kabeh Utang marang Dana Pribadi Charles River Laboratories|CRL - Rasio utang jangka dawa marang ekuitas|Rasio silihan jangka cendhak marang modal Charles River Laboratories International, Inc.|CRL - Gunggung utang perusahaan|Utang-utang marang nilai buku Charles River Lab|CRL - Utang jangka dawa perusahaan|Gunggunge utang jangka cendhak Charles River

Pambiji fundamental perusahaan:Charles River Corp CRL

To minimize the issuer's credit risks, it is necessary to assess the aggregate volume of short-term and long-term liabilities, which determines the business's dependence on external financing. The current value of 2.92 in the debt profile reflects the total amount of loans, where a decrease in this metric confirms the financial stability of Charles River Laboratories (CRL) during the implementation of costly ESG standards and energy efficiency systems across its preclinical centers.

Pesaing wigati